Challenges in Pharmacotherapy for Older Adults: a Framework for Pharmacogenomics Implementation

References

• Masnoon N , ShakibS , Kalisch-EllettL , CaugheyGE. What is polypharmacy? A systematic review of definitions. BMC Geriatrics17(1), 230 (2017).
   PubMed Web of Science ®Google Scholar
• Morin L , JohnellK , LarocheML , FastbomJ , WastessonJW. The epidemiology of polypharmacy in older adults: register-based prospective cohort study. Clin. Epidemiol.10, 289–298 (2018).
   PubMed Web of Science ®Google Scholar
• Cheung JTK , YuR , WuZ , WongSYS , WooJ. Geriatric syndromes, multimorbidity, and disability overlap and increase healthcare use among older Chinese. BMC Geriatr.18(1), 147 (2018).
   PubMedGoogle Scholar
• Maher RL , HanlonJ , HajjarER. Clinical consequences of polypharmacy in elderly. Expert Opin. Drug Saf.13(1), 57–65 (2014).
   PubMed Web of Science ®Google Scholar
• Gurwitz JH , FieldTS , HarroldLRet al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA289(9), 1107–1116 (2003).
   PubMed Web of Science ®Google Scholar
• Zhou L , RupaAP. Categorization and association analysis of risk factors for adverse drug events. Eur. J. Clin. Pharmacol.74(4), 389–404 (2018).
   PubMed Web of Science ®Google Scholar
• Daneshi N , HollidayE , HancockSet al. Prevalence of clinically actionable genotypes and medication exposure of older adults in the community. Pharmgenomics Pers. Med.10, 17–27 (2017).
   PubMed Web of Science ®Google Scholar
• Finkelstein J , FriedmanC , HripcsakG , CabreraM. Potential utility of precision medicine for older adults with polypharmacy: a case series study. Pharmgenomics Pers. Med.9, 31–45 (2016).
   PubMed Web of Science ®Google Scholar
• Boss GR , SeegmillerJE. Age-related physiological changes and their clinical significance. West J. Med.135(6), 434–440 (1981).
   PubMedGoogle Scholar
• Hammerlein A , DerendorfH , LowenthalDT. Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications. Clin. Pharmacokinet.35(1), 49–64 (1998).
   PubMed Web of Science ®Google Scholar
• Roden DM , GeorgeALJr. The genetic basis of variability in drug responses. Nat. Rev. Drug Discov.1(1), 37–44 (2002).
   PubMed Web of Science ®Google Scholar
• Haga SB , LaPointeNM. The potential impact of pharmacogenetic testing on medication adherence. Pharmacogenomics J.13(6), 481–483 (2013).
   PubMed Web of Science ®Google Scholar
• Lee YM , McKillipRP , BordenBA , KlammerCE , RatainMJ , O’DonnellPH. Assessment of patient perceptions of genomic testing to inform pharmacogenomic implementation. Pharmacogenet. Genomics.27(5), 179–189 (2017).
   PubMed Web of Science ®Google Scholar
• Swen JJ , NijenhuisM , de BoerAet al. Pharmacogenetics: from bench to byte – an update of guidelines. Clin. Pharmacol. Ther.89(5), 662–673 (2011).
   PubMed Web of Science ®Google Scholar
• Malki MA , PearsonER. Drug–drug–gene interactions and adverse drug reactions. Pharmacogenomics J.355–366 (2019).
   PubMed Web of Science ®Google Scholar
• Chong HY , LimYH , PrawjaengJ , TassaneeyakulW , MohamedZ , ChaiyakunaprukN. Cost–effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens–Johnson syndrome/toxic epidermal necrolysis in a Malaysian population. Pharmacogenet. Genomics28(2), 56–67 (2018).
   PubMed Web of Science ®Google Scholar
• Gage BF , BassAR , LinHet al. Effect of genotype-guided warfarin dosing on clinical events and anticoagulation control among patients undergoing hip or knee arthroplasty: the GIFT randomized clinical trial. JAMA318(12), 1115–1124 (2017).
   PubMed Web of Science ®Google Scholar
• Claassens DMF , VosGJA , BergmeijerTOet al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N. Engl. J. Med.381, 1621–1631 (2019).
   PubMed Web of Science ®Google Scholar
• Elliott LS , HendersonJC , NeradilekMB , MoyerNA , AshcraftKC , ThirumaranRK. Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: a prospective pilot randomized controlled trial. PLoS ONE12(2), e0170905 (2017).
   PubMed Web of Science ®Google Scholar
• Brixner D , BiltajiE , BressAet al. The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy. J. Med. Econ.19(3), 213–228 (2016).
   PubMed Web of Science ®Google Scholar
• Frigon MP , BlackburnME , Dubois-BouchardC , GagnonAL , TardifS , TremblayK. Pharmacogenetic testing in primary care practice: opinions of physicians, pharmacists and patients. Pharmacogenomics20(8), 589–598 (2019).
   PubMed Web of Science ®Google Scholar
• Chang A , NelsonR , BrixnerD. Advancing pharmacy practice by reducing gaps in pharmacogenetic education. Am. J. Health Syst. Pharm.76(5), 320–326 (2019).
   PubMed Web of Science ®Google Scholar
• Adams SM , AndersonKB , CoonsJCet al. Advancing pharmacogenomics education in the core PharmD curriculum through student personal genomic testing. Am. J. Pharm. Educ.80(1), 3 (2016).
   PubMed Web of Science ®Google Scholar
• Dunnenberger HM , BiszewskiM , BellGCet al. Implementation of a multidisciplinary pharmacogenomics clinic in a community health system. Am. J. Health Syst. Pharm.73(23), 1956–1966 (2016).
   PubMed Web of Science ®Google Scholar
• Lee KH , MinBJ , KimJH. Personal genome testing on physicians improves attitudes on pharmacogenomic approaches. PLoS ONE14(3), e0213860 (2019).
   PubMed Web of Science ®Google Scholar
• Weitzel KW , AquilanteCL , JohnsonS , KisorDF , EmpeyPE. Educational strategies to enable expansion of pharmacogenomics-based care. Am. J. Health Syst. Pharm.73(23), 1986–1998 (2016).
   PubMed Web of Science ®Google Scholar
• Dunnenberger HM , CrewsKR , HoffmanJMet al. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu. Rev. Pharmacol. Toxicol.55, 89–106 (2015).
   PubMed Web of Science ®Google Scholar
• Lemke AA , HuttenSelkirk CG , GlaserNSet al. Primary care physician experiences with integrated pharmacogenomic testing in a community health system. Per. Med.14(5), 389–400 (2017).
   PubMed Web of Science ®Google Scholar
• Luzum JA , LuzumMJ. Physicians’ attitudes toward pharmacogenetic testing before and after pharmacogenetic education. Per. Med.13(2), 119–127 (2016).
   PubMed Web of Science ®Google Scholar
• Molokhia M , MajeedA. Current and future perspectives on the management of polypharmacy. BMC Fam. Pract.18(1), 70 (2017).
   PubMedGoogle Scholar
• Martin P , TamblynR , BenedettiA , AhmedS , TannenbaumC. Effect of a pharmacist-led educational intervention on inappropriate medication prescriptions in older adults: the D-PRESCRIBE randomized clinical trial. JAMA320(18), 1889–1898 (2018).
   PubMed Web of Science ®Google Scholar
• Gardner AL , ThomasJM , MeccaMCet al. Initiative to Minimize Pharmaceutical Risk in Older Veterans (IMPROVE) polypharmacy clinic. Fed. Pract.35(11), 40–47 (2018).
   PubMedGoogle Scholar
• Zhou Y , Ingelman-SundbergM , LauschkeVM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin. Pharmacol. Ther.102(4), 688–700 (2017).
   PubMed Web of Science ®Google Scholar
• Haga SB , O’DanielJM , TindallGM , LipkusIR , AgansR. Survey of US public attitudes toward pharmacogenetic testing. Pharmacogenomics J.12(3), 197–204 (2012).
   PubMed Web of Science ®Google Scholar
• Canady VA . Growing market demand prompting genetic testing expansion. Mental Health Weekly29(31), 4–5 (2019).
   Google Scholar